Phase I results with ModraDoc006/r published in the European Journal of Cancer

October 15, 2017

14 october 2017 Researchers from the Netherlands Cancer Institute have published results from a Phase I study with oral do...

Results of Phase II Combination Trial of ISA101 and Nivolumab to be Presented at ESMO 2017

September 04, 2017

Incurable HPV16+ solid tumors treated with therapeutic cancer vaccine plus checkpoint inhibitor Leiden, The Netherlands, Sep...

Macrophage Pharma Extends Series A Round to Include New Investor Merck Ventures

August 23, 2017

Merck Ventures Joins Investment Syndicate and the Board of Macrophage 23 August 2017, Windsor, UK: Macrophage Pharma Limited ('MPL') the immuno-oncology research and development company focused on macroph...

U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron

July 28, 2017

UTRECHT, The Netherlands, July 28, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company...

Modra Pharmaceuticals Announces Start of Phase II Study for its Lead Oral Chemotherapy in Patients with Metastatic Prostate Cancer

June 14, 2017

Amsterdam, The Netherlands June 14, 2017 - Modra Pharmaceuticals today announced the initiation and the inclusion of the first patients in a Phase II study of its lead compound, ModraDoc006/r, in metastatic...

Inthera Bioscience raises CHF 10.5 million in Series A financing round

June 01, 2017

Zurich, Switzerland, May 31, 2017 - Inthera Bioscience, a Swiss biopharmaceutical company developing first-in-class targeted sm...

Updated Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO 2017

May 23, 2017

• Phase I/II trial shows significant responses of HPV16-positive patients with late-stage cervical cancer Leiden, The Netherlands, May 23, 2017 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy c...

Merus Announces Promising Results from MCLA-128 Phase 1/2 Study in Metastatic Breast Cancer

May 17, 2017

Results to be presented at the 2017 American Society of Clinical Oncology Annual Meeting Phase 2 clinical trial to be initia...

Macrophage Pharma Appoints Development Director

May 11, 2017

Dr Joanne Bedwell-Garner joins management team Windsor, England, May 11, 2017. Macrophage Pharma Limited ('MPL') the immuno-o...

CIMT to honor Dutch immuno-haematologist Cornelis Melief with lifetime achievement award

May 10, 2017

On May 10, 2017, the Dutch immuno-haematologist Prof. Dr. Cornelis (Kees) Melief will be honored for life-time achievements in...

Merus Named BioCapital Europe 2017 Company of the Year

March 16, 2017

Award Recognizes Company's Substantial Transformation and Breakthroughs Over Past 12 Months UTRECHT, The Netherlands, March...

Results of Cervical Cancer Study Sponsored by ISA Pharmaceuticals to Be Presented at ASCO-SITC

February 16, 2017

- First data of phase I/II trial in HPV16-positive patients with late-stage cervical cancer Leiden, The Netherlands, Februar...

Merus Announces Closing of Global Strategic Research Collaboration with Incyte to Discover and Develop Bispecific Antibodies

January 23, 2017

UTRECHT, The Netherlands, Jan. 23, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closi...

Cristal Therapeutics raises €12.8 million in new financing round to advance novel medicines against cancer using its CriPec® nanotech platform

January 19, 2017

Round led by Aglaia BioMedical Ventures and DROIA Oncology Ventures. Funding used: - to execute clinical phase Ib and phase...

Macrophage Pharma Raises £9 Million in Series A Financing and Acquires Immune-oncology Technology Platform

January 09, 2017

WINDSOR, England, January 9, 2017 /PRNewswire/ -- Macrophage Pharma Limited, a newly formed immune-oncology company, today announced that it has successfully raised £9 million in a Series A equity financi...

Merus and the Institute for Research in Biomedicine (IRB) Barcelona Form Research Collaboration to Develop Bispecific Antibodies Targeting the Tumor Microenvironment

January 05, 2017

UTRECHT, The Netherlands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, and the Institute for Re...

Incyte and Merus Announce Global Strategic Research Collaboration to Discover and Develop Bispecific Antibodies

December 21, 2016

Collaboration designed to leverage Merus' Biclonics® bispecific antibody technology to expand Incyte's discovery capabilities and large-molecule portfolio Incyte to make up-front payment of $120 mi...

ISA Pharmaceuticals Advances Personalized Cancer Treatment

December 07, 2016

- Next-generation immunotherapy called MyISA® for individual cancer patients Leiden, The Netherlands, December 7, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the re...

ISA Pharmaceuticals Appoints Bart Bergstein as Chairman of the Supervisory Board

June 03, 2016

Leiden, The Netherlands, June 03, 2016 - ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, to...

Merus N.V. Signs Commercial Multi-Product License for ProBioGen’s GlymaxX® ADCC Enhancement Technology

June 01, 2016

Bispecific Cancer Antibody Pipeline Optimized by GlymaxX® Manufacturing Technology BERLIN & UTRECHT, The Netherlands, June 01, 2016 (GLOBE NEWSWIRE) -- ProBioGen AG and Merus N.V. (Nasdaq:MRUS) today join...